Catch 22 for Big Pharma as China Bulk Buying Plan Goes National

(Bloomberg) -- Global drug makers like AstraZeneca Plc are facing the prospect of having to drop prices by half to maintain their sales to China’s biggest public hospitals, as the country’s aggress...